AIT Therapeutics (AITB) Given a $16.00 Price Target at Roth Capital

AIT Therapeutics (OTCMKTS:AITB) has been assigned a $16.00 target price by stock analysts at Roth Capital in a note issued to investors on Saturday. The brokerage presently has a “buy” rating on the stock. Roth Capital’s price objective indicates a potential upside of 185.71% from the company’s current price.

Several other analysts also recently weighed in on the stock. Laidlaw began coverage on shares of AIT Therapeutics in a report on Thursday, August 24th. They issued a “buy” rating and a $16.00 target price on the stock. Ladenburg Thalmann Financial Services began coverage on shares of AIT Therapeutics in a report on Monday, August 7th. They issued a “buy” rating on the stock.

Shares of AIT Therapeutics (OTCMKTS AITB) traded down $0.50 during trading hours on Friday, hitting $5.60. 7,038 shares of the stock traded hands, compared to its average volume of 15,624. AIT Therapeutics has a 1-year low of $4.32 and a 1-year high of $10.00.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at

About AIT Therapeutics

AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.

Receive News & Ratings for AIT Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply